Donepezil | Placebo | Treatment effect* | P values | ||
Means (SEM) | Means (SEM) | Means | (95%CI) | ||
Psychosis | |||||
Cx in total PPQ | −0.12 (0.152) | 0.53 (0.166) | −0.652 | (−1.095to−0.209) | 0.004 |
Sleepiness | |||||
Cx in ESS | 0.36(0.45) | 1.69(0.47) | −1.33 | (−2.61to−0.05) | 0.042 |
Cognitive function | |||||
Cx in scores of MMSE | 0.02 (0.28) | −0.78 (0.25) | 0.8 | (0.07to1.54) | 0.032 |
Cx in WMS-1 (auditory memory) | 11.2 (1.48) | 7.06 (1.20) | 4.15 | (0.43to7.87) | 0.029 |
Cx in WMS-2 (visual memory) | 3.85 (0.66) | 3.32 (0.80) | 0.53 | (−1.50to2.56) | 0.609 |
Cx in WMS-4 (attention) | 1.02 (0.87) | 0.92 (0.97) | 0.1 | (−2.46to2.66) | 0.94 |
Cx in FAB | 0.07 (0.22) | 0.39 (0.23) | −0.32 | (−0.94to0.32) | 0.315 |
Higher scores in PPQand ESSare worse.
Higher scores in MMSE, WMSand FAB are better.
*Effect size was estimated using GEE (working matrix M-dependent).
Cx: changes; ESS, Epworth Sleep Scale; FAB,Frontal Assessment Battery;GEE,generalised estimating equation; MMSE,Mini-Mental State Examination; PPQ,Parkinson’s Psychosis Questionnaire;WMS,Wechsler Memory Scale.